Cigna infliximab criteria for ophthalmic indications

Cigna updated infliximab authorization criteria for ophthalmology effective 2026-03-15, adding condition-specific eligibility, dosing, and duration rules for Behcet’s disease with ocular involvement, scleritis/sterile corneal ulceration, and uveitis (including posterior uveitides and panuveitis). Initial approvals are time-limited (Behcet’s 3 months; scleritis and uveitis 6 months) with defined age cutoffs and prior-therapy requirements or specified exceptions (prior TNF inhibitor or other biologic). Continuation approvals are 1 year for established responders who have been on therapy for the specified induction period and demonstrate objective or symptomatic improvement; prescriber or ophthalmology consultation requirements are specified. Dosing caps and induction/maintenance schedules are detailed by indication, and the policy operationalizes guideline principles into measurable authorization criteria.

This revision reflects the documented effective date of 2026-03-15 for Cigna's Drug Coverage Policy IP0660 addressing infliximab use in ophthalmology-related indications. The document consolidates explicit, condition-specific coverage criteria and duration limits for infliximab across several ophthalmic inflammatory conditions — notably Behcet's disease with ophthalmic manifestations, scleritis or sterile corneal ulceration, and uveitis (including other posterior uveitides and panuveitis). The policy text also reiterates dosing regimens and differentiated initial versus continuation approval pathways for these indications.

Compared with prior practice statements cited in the guidelines section (e.g., AAO 2014 and EULAR 2018), the policy operationalizes those guideline principles into definable authorization criteria: patient age thresholds, prior therapy requirements or allowed exceptions, prescriber specialty consultation requirements, objective response measures for renewal, and specific durations of initial and continuation approvals.

The policy defines separate approval pathways for Behcet's disease with ophthalmic involvement. For initial therapy, infliximab may be approved for 3 months when the patient is older than 6 years, has either tried at least one conventional therapy (examples provided) or has ophthalmic manifestations of Behcet's disease, and the medication is prescribed by or in consultation with a rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist. An exception waives the conventional-therapy trial if the patient already had a trial of at least one TNF inhibitor; prior use of a different biologic also satisfies the trial requirement.

For scleritis or sterile corneal ulceration, the policy sets an initial approval period of 6 months for patients over 18 years who have tried at least one other therapy (examples listed include NSAIDs, corticosteroids, methotrexate, cyclosporine, or other immunosuppressants) and when prescribed by or in consultation with an ophthalmologist. Current infliximab recipients can receive a 1-year approval if established on therapy for at least 6 months and they meet renewal evidence criteria.

Renewal evidence for these indications requires either objective improvement from baseline (examples include serum inflammatory markers) or symptomatic improvement such as decreased eye pain, redness, photophobia, tearing, or improved visual acuity. The policy explicitly frames these objective and symptomatic benchmarks as necessary to continue annual authorization.

For uveitis (including posterior uveitides and panuveitis), initial infliximab approval is for 6 months for patients older than 6 years who have tried periocular, intraocular, or systemic corticosteroids or immunosuppressives (examples enumerated). The policy allows exceptions when a patient already had a trial of an etanercept or adalimumab product or has previously tried another biologic; biosimilars of the requested biologic do not count as fulfilling prior-biologic requirements. The prescribing clinician must be an ophthalmologist or consult one.

Continuing therapy approvals are available for 1 year for patients on infliximab at least 6 months who demonstrate either objective improvement (e.g., best-corrected visual acuity, lesion assessment, anterior chamber cell grade, or vitreous haze grade) or symptomatic improvement (e.g., reduced eye pain, redness, photophobia, blurred vision, or improved visual acuity). Dosing for initial uveitis therapy is specified up to 10 mg/kg with induction doses followed by maintenance no more frequently than once every 4 weeks; continuation dosing may be up to 10 mg/kg no more frequently than every 4 weeks.

The policy standardizes dosing and approval pathways for several non-ophthalmic and related scenarios referenced in the document. For immunotherapy-related toxicities due to checkpoint inhibitor therapy, initial infliximab dosing is allowed up to 5 mg/kg with specific induction timing (baseline, then 2 and 6 weeks) and maintenance no more frequently than once every 6 weeks; current users may be approved up to 10 mg/kg no more frequently than every 4 weeks. For other indications such as spondyloarthritis subtypes and certain gastrointestinal or systemic inflammatory diseases, the policy references guideline recommendations (AGA, ACG, EULAR, AAO) when defining the role of TNF inhibitors, but the operationalized criteria in this document focus on the ophthalmology-related indications detailed above.

Across indications, the policy distinguishes initial-therapy short-term approvals (3–6 months depending on indication) from 1-year renewals for established responders, and it requires objective measures or symptomatic improvement to qualify for continuation.

OpenPayer

March 2026 Revision: Condition-Specific Infliximab Criteria and Durations

Behcet's Disease with Ophthalmic Manifestations: Eligibility, Duration, and Renewal Evidence

Scleritis and Sterile Corneal Ulceration: Age, Prior Therapy, and Renewal Requirements

Uveitis: Prior-Therapy Exceptions, Prescriber Requirement, Objective Measures, and Dosing

Dosing Standards and Cross-Indication Authorization Patterns (Including Checkpoint-Inhibitor Toxicities)